Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. Westby M, et al. J Virol. 2006 May;80(10):4909-20. doi: 10.1128/JVI.80.10.4909-4920.2006. J Virol. 2006. PMID: 16641282 Free PMC article. Clinical Trial.
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
Lewis M, Mori J, Toma J, Mosley M, Huang W, Simpson P, Mansfield R, Craig C, van der Ryst E, Robertson DL, Whitcomb JM, Westby M. Lewis M, et al. Among authors: westby m. PLoS One. 2018 Dec 26;13(12):e0204099. doi: 10.1371/journal.pone.0204099. eCollection 2018. PLoS One. 2018. PMID: 30586365 Free PMC article. Clinical Trial.
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.
Lewis ME, Simpson P, Mori J, Jubb B, Sullivan J, McFadyen L, van der Ryst E, Craig C, Robertson DL, Westby M. Lewis ME, et al. Among authors: westby m. Antivir Chem Chemother. 2021 Jan-Dec;29:20402066211030380. doi: 10.1177/20402066211030380. Antivir Chem Chemother. 2021. PMID: 34343443 Free PMC article.
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Flynn JK, Ellenberg P, Duncan R, Ellett A, Zhou J, Sterjovski J, Cashin K, Borm K, Gray LR, Lewis M, Jubb B, Westby M, Lee B, Lewin SR, Churchill M, Roche M, Gorry PR. Flynn JK, et al. Among authors: westby m. AIDS Res Hum Retroviruses. 2017 Dec;33(12):1220-1235. doi: 10.1089/AID.2017.0097. Epub 2017 Sep 26. AIDS Res Hum Retroviruses. 2017. PMID: 28797170
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Jubb B, Lewis M, McFadyen L, Simpson P, Mori J, Chan P, Weatherley B, van der Ryst E, Westby M, Craig C. Jubb B, et al. Among authors: westby m. Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619895706. doi: 10.1177/2040206619895706. Antivir Chem Chemother. 2019. PMID: 31856576 Free PMC article. Clinical Trial.
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M. Flynn JK, et al. Among authors: westby m. Virology. 2013 Jul 20;442(1):51-8. doi: 10.1016/j.virol.2013.03.026. Epub 2013 Apr 17. Virology. 2013. PMID: 23602007 Free article.
130 results